A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This will be a nonrandomized, single arm feasibility study with the primary goal of
evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients
with advanced/metastatic HCC with Child-Pugh B7 liver disease who have received no prior
systemic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Kristen Spencer
Collaborators:
Genentech, Inc. Rutgers Cancer Institute of New Jersey